Free Trial
NASDAQ:SNDX

Syndax Pharmaceuticals (SNDX) Stock Price, News & Analysis

Syndax Pharmaceuticals logo
$8.87 -0.13 (-1.44%)
As of 10:34 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Syndax Pharmaceuticals Stock (NASDAQ:SNDX)

Key Stats

Today's Range
$8.85
$9.23
50-Day Range
$8.82
$14.15
52-Week Range
$8.58
$25.07
Volume
187,375 shs
Average Volume
1.83 million shs
Market Capitalization
$763.26 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$35.80
Consensus Rating
Moderate Buy

Company Overview

Syndax Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
63rd Percentile Overall Score

SNDX MarketRank™: 

Syndax Pharmaceuticals scored higher than 63% of companies evaluated by MarketBeat, and ranked 409th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Syndax Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 9 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Syndax Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

  • Read more about Syndax Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Syndax Pharmaceuticals are expected to decrease in the coming year, from ($3.72) to ($4.25) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Syndax Pharmaceuticals is -2.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Syndax Pharmaceuticals is -2.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Syndax Pharmaceuticals has a P/B Ratio of 2.66. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Syndax Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    26.66% of the float of Syndax Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Syndax Pharmaceuticals has a short interest ratio ("days to cover") of 10, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Syndax Pharmaceuticals has recently decreased by 4.93%, indicating that investor sentiment is improving.
  • Dividend Yield

    Syndax Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Syndax Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    26.66% of the float of Syndax Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Syndax Pharmaceuticals has a short interest ratio ("days to cover") of 10, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Syndax Pharmaceuticals has recently decreased by 4.93%, indicating that investor sentiment is improving.
  • News Sentiment

    Syndax Pharmaceuticals has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.90 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Syndax Pharmaceuticals this week, compared to 6 articles on an average week.
  • Search Interest

    Only 1 people have searched for SNDX on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
Receive SNDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Syndax Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SNDX Stock News Headlines

Syndax Pharmaceuticals, Inc. (SNDX) - Yahoo Finance
This Signal Only Flashes Once Every 4 Years – And It Just Triggered
This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in crypto. Now it’s back, and the smart money is already positioning. A free training reveals the step-by-step strategy and altcoin picks designed to help you capitalize on the next wave.
SNDX Syndax Pharmaceuticals, Inc. - Seeking Alpha
See More Headlines

SNDX Stock Analysis - Frequently Asked Questions

Syndax Pharmaceuticals' stock was trading at $13.22 at the beginning of 2025. Since then, SNDX shares have decreased by 31.9% and is now trading at $9.00.
View the best growth stocks for 2025 here
.

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) issued its earnings results on Monday, May, 5th. The company reported ($0.98) earnings per share for the quarter, beating analysts' consensus estimates of ($1.04) by $0.06. The firm's revenue for the quarter was up 1900.0% compared to the same quarter last year.
Read the conference call transcript
.

Syndax Pharmaceuticals (SNDX) raised $66 million in an initial public offering (IPO) on Thursday, March 3rd 2016. The company issued 4,400,000 shares at $14.00-$16.00 per share. Morgan Stanley and Citigroup served as the underwriters for the IPO and JMP Securities and Oppenheimer & Co. were co-managers.

Shares of SNDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Syndax Pharmaceuticals investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), Novo Nordisk A/S (NVO) and ServiceNow (NOW).

Company Calendar

Last Earnings
5/05/2025
Today
7/02/2025
Next Earnings (Estimated)
8/07/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:SNDX
Employees
110
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$35.80
High Stock Price Target
$51.00
Low Stock Price Target
$17.00
Potential Upside/Downside
+297.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.90
Research Coverage
10 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$318.76 million
Net Margins
-757.53%
Pretax Margin
-757.52%

Debt

Sales & Book Value

Annual Sales
$23.68 million
Price / Cash Flow
N/A
Book Value
$3.38 per share
Price / Book
2.66

Miscellaneous

Free Float
82,519,000
Market Cap
$774.45 million
Optionable
Optionable
Beta
0.70

Social Links

20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

This page (NASDAQ:SNDX) was last updated on 7/3/2025 by MarketBeat.com Staff
From Our Partners